Schachter SC. Overview of the management of epilepsy in adults. In: Post TW, editor. UpToDate [Internet]. Waltham (MA): UpToDate; 2016 Mar 29 [cited 2016 May 25]. Available from: www​.uptodate.com Subscription required.

Brivlera (brivaracetam) 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg tablets, 10mg/mL oral solution and 10 mg/mL injection [product monograph]. Oakville (ON): UCB Canada Inc.; 2016 Mar 9.

Strzelczyk A, Klein KM, Willems LM, Rosenow F, Bauer S. Brivaracetam in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus. Expert Rev Clin Pharmacol. 2016 May;9(5):637–45. [PubMed: 26891946]

CDR submission: Brivlera (brivaracetam) 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg tablets, 10mg/mL oral solution and 10 mg/mL injection. Company: UCB Canada Inc. [CONFIDENTIAL manufacturer’s submission]. Oakville (ON): UCB Canada Inc.; 2016 Apr 15.

Health Canada reviewer’s report: Brivlera (brivaracetam) [CONFIDENTIAL internal report]. Ottawa: Therapeutics Products Directorate, Health Canada; 2016 Mar 8.

BresMed. UCB: Brivaracetam: NMA versus branded AEDs [CONFIDENTIAL internal manufacturer’s report]. [Sheffield (United Kingdom)]: BresMed; 2016 Mar 1.

Zhang L, Li S, Li H, Zou X. Levetiracetam vs. brivaracetam for adults with refractory focal seizures: a meta-analysis and indirect comparison. Seizure. 2016 May 16;39:28–33. [PubMed: 27236448]

Toledo M, Whitesides J, Schiemann J, Johnson ME, Eckhardt K, McDonough B, et al. Safety, tolerability, and seizure control during long-term treatment with adjunctive brivaracetam for partial-onset seizures. Epilepsia. 2016 Jul;57(7):1139–51. [PubMed: 27265725]

Common Drug Review. CEDAC final recommendation: lacosamide (Vimpat - UCB Canada Inc.). Indication: epilepsy, partial-onset seizures [Internet]. Ottawa: CADTH; 2011 Apr 25. [cited 2016 May 25]. Available from: https://www​.cadth.ca​/sites/default/files​/cdr/complete/cdr_complete​_Vimpat_April-29-11.pdf

CADTH Canadian Drug Expert Committee (CDEC) final recommendation: eslicarbazepine acetate (Aptiom — Sunovion Pharmaceuticals Canada Inc.) Indication: partial-onset seizures in patients with epilepsy [Internet]. Ottawa: CADTH; 2015 Apr 16. [cited 2016 May 25]. Available from: https://www​.cadth.ca​/sites/default/files​/cdr/complete/cdr_complete​_SR0391_Aptiom_Apr-20-15.pdf Revised June 24, 2015.

CADTH Canadian Drug Expert Committee (CDEC) final recommendation: perampanel (Fycompa - Eisai Limited). Indication: epilepsy, partial-onset seizures [Internet]. Ottawa: CADTH; 2013 Oct 17. [cited 2016 May 25]. Available from: https://www​.cadth.ca​/sites/default/files​/cdr/complete/cdr_complete​_Fycompa_October-21-13_e.pdf

CADTH Canadian Drug Expert Committee (CDEC) final recommendation: perampanel (Fycompa - Eisai Limited). Indication: epilepsy, primary generalized tonic-clonic seizures [Internet]. Ottawa: CADTH; 2016 May 18. [cited 2016 May 25]. Available from: https://www​.cadth.ca​/sites/default/files​/cdr/complete/SR0458​_complete_Fycompa_May-20-16_e.pdf

Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000 Feb 3;342(5):314–9. [PubMed: 10660394]

Clinical study report: N01252. A multi-center, double-blind, parallel-group, placebo-controlled, randomized study: evaluation of the efficacy and safety of brivaracetam in subjects (³16 to 70 years old) with partial onset seizures [CONFIDENTIAL internal manufacturer’s report]. Brussels (Belgium): UCB Pharma SA; 2010 Jul 26.

Clinical study report: N01253. An international, double-blind, parallel-group, placebo-controlled, randomized study: evaluation of the efficacy and safety of brivaracetam in subjects (³16 to 70 years old) with partial onset seizures [CONFIDENTIAL internal manufacturer’s report]. Smyrna (GA): UCB Inc.; 2011 Jun 3.

Clinical study report: N01254. An international, randomized, double-blind, parallel-group, placebo-controlled, flexible dose study: evaluation of the safety and efficacy of brivaracetam in subjects (³16 to 70 years old) suffering from localization-related or generalized epilepsy [CONFIDENTIAL internal manufacturer’s report]. Brussels (Belgium): UCB Pharma S.A.; 2010 Jul 6.

Clinical study report: N01358. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of brivaracetam in subjects (³16 to 80 years old) with partial-onset seizures [CONFIDENTIAL internal manufacturer’s report]. Raleigh (NC): UCB Biosciences, Inc.; 2014 Sep 19.

Mapping connections: an understanding of neurological conditions in Canada. The national population health study of neurological conditions [Internet]. Ottawa: Public Health Agency of Canada; 2014 Dec 9. [cited 2016 May 25]. Available from: http://www​.phac-aspc​.gc.ca/publicat/cd-mc/mc-ec/index-eng​.php

Epilepsy facts [Internet]. Markham (ON): Epilepsy Canada; 2016. [cited 2016 May 25]. Available from: http://www​.epilepsy.ca/epilepsy-facts​.html

Sirven JI. Evaluation and management of drug-resistant epilepsy. In: Post TW, editor. UpToDate [Internet]. Waltham (MA): UpToDate; 2016 Mar 14 [cited 2016 May 25]. Available from: www​.uptodate.com Subscription required.

Aptiom (eslicarbazepine acetate) 200 mg, 400 mg, 600 mg and 800 mg tablets [product monograph]. Mississauga (ON): Sunovion Pharmaceuticals Canada Inc.; 2014 Jul 4.

Ryvlin P, Werhahn KJ, Blaszczyk B, Johnson ME, Lu S. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial. Epilepsia. 2014 Jan;55(1):47–56. [PubMed: 24256083]

Biton V, Berkovic SF, Abou-Khalil B, Sperling MR, Johnson ME, Lu S. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial. Epilepsia. 2014 Jan;55(1):57–66. [PubMed: 24446953]

Kwan P, Trinka E, Van Paesschen W, Rektor I, Johnson ME, Lu S. Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial. Epilepsia. 2014 Jan;55(1):38–46. [PubMed: 24116853]

Klein P, Schiemann J, Sperling MR, Whitesides J, Liang W, Stalvey T, et al. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia. 2015 Dec;56(12):1890–8. [PubMed: 26471380]

Center for Drug Evaluation and Research, U.S. Food and Drug Administration. Medical review(s). In: Briviact (brivaracetam). Company: UCB Inc. Application no.: 205836, 205837, 205838. Approval date: 16/02/2016 [Internet]. Rockville (MD): FDA; 2015 Nov 20 [cited 2016 May 10]. (FDA drug approval package). Available from: http://www​.accessdata​.fda.gov/drugsatfda_docs​/nda/2016/205836Orig1s000​_205837Orig1s000​_205838Orig1s000MedR.pdf

Center for Drug Evaluation and Research, U.S. Food and Drug Administration. Statistical review(s). In: Briviact (brivaracetam). Company: UCB Inc. Application no.: 205836, 205837, 205838. Approval date: 16/02/2016 [Internet]. Rockville (MD): FDA; 2016 Jan 15 [cited 2016 May 10]. (FDA drug approval package). Available from: http://www​.accessdata​.fda.gov/drugsatfda_docs​/nda/2016/205836Orig1s000​_205837Orig1s000​_205838Orig1s000StatR.pdf

UCB Canada response to June 16, 2016 CDR request for additional information regarding the Brivlera CDR review: history of vagal nerve stimulation at study entry (ITT population or ITT POS population) [CONFIDENTIAL additional manufacturer’s information]. Oakville (ON): UCB Canada; 2016 Jun 24.

UCB Canada response to June 16, 2016 CDR request for additional information regarding the Brivlera CDR review: history of surgical procedures at study entry (ITT population or ITT POS population) [CONFIDENTIAL additional manufacturer’s information]. Oakville (ON): UCB Canada; 2016 Jun 29.

Cramer JA, Perrine K, Devinsky O, Bryant-Comstock L, Meador K, Hermann B. Development and cross-cultural translations of a 31-item quality of life in epilepsy inventory. Epilepsia. 1998 Jan;39(1):81–8. [PubMed: 9578017]

Borghs S, de la Loge C, Cramer JA. Defining minimally important change in QOLIE-31 scores: estimates from three placebo-controlled lacosamide trials in patients with partial-onset seizures. Epilepsy Behav. 2012 Mar;23(3):230–4. [PubMed: 22341962]

Wiebe S, Matijevic S, Eliasziw M, Derry PA. Clinically important change in quality of life in epilepsy. J Neurol Neurosurg Psychiatry [Internet]. 2002 Aug [cited 2016 Jun 17];73(2):116–20. Available from: http://www​.ncbi.nlm.nih​.gov/pmc/articles/PMC1737966 [PMC free article: PMC1737966] [PubMed: 12122166]

Brooks R. EuroQol: the current state of play. Health Policy. 1996 Jul;37(1):53–72. [PubMed: 10158943]

EuroQol Group. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990 Dec;16(3):199–208. [PubMed: 10109801]

Snaith RP. The Hospital Anxiety And Depression Scale. Health Qual Life Outcomes [Internet]. 2003 [cited 2016 Jun 17];1:29. Available from: http://www​.ncbi.nlm.nih​.gov/pmc/articles/PMC183845 [PMC free article: PMC183845] [PubMed: 12914662]

Wiglusz MS, Landowski J, Michalak L, Cubala WJ. Validation of the Hospital Anxiety and Depression Scale in patients with epilepsy. Epilepsy and Behavior. 2016;58:97–101. [PubMed: 27064829]

Devinsky O, Vickrey BG, Cramer J, Perrine K, Hermann B, Meador K, et al. Development of the quality of life in epilepsy inventory. Epilepsia. 1995 Nov;36(11):1089–104. [PubMed: 7588453]

Cramer JA, Van Hammee G, N132 Study Group. Maintenance of improvement in health-related quality of life during long-term treatment with levetiracetam. Epilepsy Behav. 2003 Apr;4(2):118–23. [PubMed: 12697135]

Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983 Jun;67(6):361–70. [PubMed: 6880820]

de Oliveira GN, Lessa JM, Goncalves AP, Portela EJ, Sander JW, Teixeira AL. Screening for depression in people with epilepsy: comparative study among neurological disorders depression inventory for epilepsy (NDDI-E), hospital anxiety and depression scale depression subscale (HADS-D), and Beck depression inventory (BDI). Epilepsy Behav. 2014 May;34:50–4. [PubMed: 24681386]

Sinnot PL, Joyce VR, Barnett PG. Guidebook: preference measurement in economic analysis [Internet]. Menlo Park (CA): Health Economics Resource Center (HERC); 2007 Mar. [cited 2016 Apr 20]. Available from: http://www​.herc.research​.va.gov/files/BOOK_419.pdf

Sullivan PW, Lawrence WF, Ghushchyan V. A national catalog of preference-based scores for chronic conditions in the United States. Med Care. 2005 Jul;43(7):736–49. [PubMed: 15970790]

Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res. 2005 Aug;14(6):1523–32. [PubMed: 16110932]

Yates SL, Fakhoury T, Liang W, Eckhardt K, Borghs S, D’Souza J. An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam. Epilepsy Behav. 2015 Nov;52(Pt A):165–8. [PubMed: 26432008]

Lattanzi S, Cagnetti C, Foschi N, Provinciali L, Silvestrini M. Brivaracetam add-on for refractory focal epilepsy: a systematic review and meta-analysis. Neurology. 2016 Apr 5;86(14):1344–52. [PubMed: 26944275]

French JA, Costantini C, Brodsky A, von Rosenstiel P, N01193 Study Group. Adjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trial. Neurology. 2010 Aug 10;75(6):519–25. [PubMed: 20592253]